Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Impact of mast cells on multiple sclerosis: inhibitory effect of natalizumab.
Partial suppression of M1 microglia by Janus kinase 2 inhibitor does not protect against neurodegeneration in animal models of amyotrophic lateral sclerosis.
Diffusion tensor imaging of the trigeminal nerve in patients with trigeminal neuralgia due to multiple sclerosis.
The Nogo/ Nogo-66 receptor (NgR) signal is involved in neuroinflammation through the regulation of microglia inflammatory mediator expression.
Neuromyelitis optica spectrum disorders: An update.
Casein kinases as potential therapeutic targets.
Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology.
Isolation of highly enriched primary human microglia for functional studies.
Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III).
Employment and multiple sclerosis in new zealand.
Functional correlates of cognitive dysfunction in multiple sclerosis: A multicenter fMRI Study.
[Assessment of exposure to tobacco smoke in a selected group of patients with multiple sclerosis from the Upper Silesia region].
Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits.
Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.
Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study.
The relationship of age with the clinical phenotype in multiple sclerosis.
FDG PET/CT in Acute Tumefactive Multiple Sclerosis Occurring in a Case of Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
Time to target brain atrophy and neurodegeneration in multiple sclerosis.
Multiple sclerosis and the role of immune cells.
Longitudinal assessment of clinically isolated syndrome with diffusion tensor imaging and volumetric MRI.
Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis.
EN FACE OPTICAL COHERENCE TOMOGRAPHY OF MACULAR MICROCYSTS DUE TO OPTIC NEUROPATHY FROM NEUROMYELITIS OPTICA.
Evolution of the CNS myelin gene regulatory program.
Transient widespread cortical and splenial lesions in acute encephalitis/encephalopathy associated with primary Epstein-Barr virus infection.
Interleukin-8 is associated with acute and persistent dysfunction after optic neuritis.
Pages
« first
‹ previous
…
572
573
574
575
576
577
578
579
580
…
next ›
last »